Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T19:12:44.644Z.
Calculation as of: 2026-10-06T19:12:44.644Z.
Quote observation: 2026-10-06T19:10:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 65e01e2061821370315a71c231e2ba412a336584d38d2dbcbde0d0d1c3e2cd16
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Mobia Medical, Inc. Common Stock
Market Cap
$294.92M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$292.57M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$292.16M
Operating Cash Flow Yield
N/A
TTM Avg
41.23%
3Y Avg
41.23%
5Y Avg
41.23%
Market Cap
$286.29M
Operating Cash Flow Yield
N/A
TTM Avg
1.81%
3Y Avg
1.81%
5Y Avg
1.81%
Market Cap
$285.74M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$284.62M
Operating Cash Flow Yield
N/A
TTM Avg
2.67%
3Y Avg
2.67%
5Y Avg
2.67%
Market Cap
$283.58M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$281.92M
Operating Cash Flow Yield
N/A
TTM Avg
1.84%
3Y Avg
1.84%
5Y Avg
1.84%
Market Cap
$310.56M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mobia Medical, Inc. Common Stock (MOBI) | $294.92M | N/A | N/A | N/A | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $292.57M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $292.16M | N/A | 41.23% | 41.23% | 41.23% |
| Abeona Therapeutics Inc. (ABEO)vs › | $286.29M | N/A | 1.81% | 1.81% | 1.81% |
| Sagimet Biosciences Inc. (SGMT)vs › | $285.74M | N/A | N/A | N/A | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $284.62M | N/A | 2.67% | 2.67% | 2.67% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $283.58M | N/A | N/A | N/A | N/A |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.92M | N/A | 1.84% | 1.84% | 1.84% |
| Benitec Biopharma Inc. (BNTC)vs › | $310.56M | N/A | N/A | N/A | N/A |
| Standard BioTools Inc. (LAB)vs › | $281.81M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
